Participated · Equity · Nov 2024

TailorMed provides an enterprise platform that manages the full lifecycle of patient support programs to reduce cost barriers and improve medication access and adherence. The company has built the nation’s largest Affordability Network, deployed across more than 800 hospitals, 1,300 clinics, and 650 pharmacies. TailorMed integrates directly with manufacturer assistance programs to automate patient support and streamline stakeholder workflows. Having reached an inflection point in its network evolution, the company is expanding into an end-to-end platform to tackle cost, access, and adherence across the medication continuum. The new financing will fund that expansion and broader efforts to create a seamless flow of data and resources across patients, providers, pharmacies, life sciences, and payers. TailorMed frames this work as addressing affordability at the point a prescription is written or dispensed to prevent delayed or skipped treatments. TailorMed Medical provides a technology platform that automates identification of financially at-risk patients and matches and enrolls them in financial resources such as co-pay assistance, replacement drug programs, government subsidies, community and state resources, disease-specific foundations, and programs addressing living expenses. Its platform is designed to reduce out-of-pocket responsibility for patients, helping to eliminate downstream financial hardship and avoidance of care. For health organizations, TailorMed shifts financial assistance from reactive matching or downstream collections to a proactive, point-of-care approach. The company serves physician practices, specialty clinics and health systems, and in 2021 expanded adoption into pharmacies nationwide. TailorMed said it will use the new funding to further expand its reach across health care with innovative financial solutions. Srulik Dvorsky is CEO and co-founder and the company is based in New York City.

Participated · Series D · Jun 2023

Augmedics develops an AR-based navigation platform (branded Xvision) combining custom hardware and software to display digitized CT scans from a surgeon’s perspective. Its system, FDA-cleared in 2019 and commercially deployed in 2020, has been used in over 4,000 procedures and is installed in more than 70 U.S. hospitals. The platform can replace fluoroscopy in some non-invasive procedures and provides continuous intraoperative spine visualization in more invasive operations. The company emphasizes purpose-built hardware optimized for surgical use rather than off-the-shelf AR gear. Management plans to use new funding to build the next generation of the platform and accelerate commercial development while remaining focused on spinal applications. It has also received inbound interest for extensions into other musculoskeletal and cranial procedures that use CT/MRI imaging. Augmedics develops the xvision Spine System, the first and only FDA‑cleared augmented reality surgical image guidance system that lets surgeons visualize 3D spinal anatomy and navigate instruments while looking directly at the patient. The company received FDA 510(k) clearance in December 2019 and began U.S. sales in the second half of 2020. By year-end 2020 the system had been used in over 250 spinal surgeries. Augmedics plans to commercialize more broadly across the U.S. and into OUS markets, pursue CE certification for Europe, develop next‑generation products, and expand to new indications. Financially, the company has raised $63 million to date following a recent $36 million Series C and an earlier $21 million Series B. Augmedics develops the xvision Spine (XVS), an augmented reality surgical image-guidance system that enables surgeons to visualize a patient’s 3D spinal anatomy during surgery. XVS is designed to let surgeons accurately navigate instruments and implants while looking directly at the patient rather than a remote screen. The company received FDA 510(k) clearance and launched XVS in the U.S. in December 2019. The system is being used in renowned hospitals and surgical centers in the U.S. In June 2020 Augmedics completed a $15M Series B round that included staff investment and SAFE conversions. Leadership cited in the article includes founder and CEO Nissan Elimelech and President and CCO Tim Murawski. Augmedics develops the ViZOR, an augmented-reality surgical visualization system that projects a 3D image of a patient’s spine onto a surgeon’s retina in real time using proprietary see-through AR optics. The ViZOR is intended initially for minimally invasive spine surgeries to reduce operative time, radiation exposure and unnecessary repeat operations or hospitalizations. Augmedics plans to complete R&D and conduct pre-clinical and clinical trials of The ViZOR, and to pursue 510(k) clearance from the U.S. FDA. Future product development includes integrating sensors to collect surgical data and applying deep learning to provide suggestions, alerts and other intraoperative assistance. The company has received industry honors and previously raised seed financing from the TerraLab incubator (an incubator of the Israeli Innovation Authority). Financially, it recently secured an $8.3 million Series A to advance regulatory and commercialization efforts.

Participated · Series A · Jan 2022

Sensi.AI has built an audio-based Care Intelligence platform that equips home-care agencies and family caregivers with real-time insights into a senior’s physical, cognitive and emotional status. The system’s Care Agent passively monitors the home environment, detects and predicts care events, and offers in-the-moment guidance; complementary Growth and Ops Agents automate demand management and administrative workflows for agencies. The technology is fueled by one of the largest in-home care datasets, allowing its AI models to improve accuracy and breadth of insights over time. Sensi partners with renowned dementia expert Teepa Snow to deliver personalized coaching through the platform. With its latest financing, the company plans to accelerate product innovation and intensify go-to-market expansion. Headquartered in Palo Alto, Sensi.AI has now secured more than $98 million in total funding, underscoring investor confidence in its approach to aging-in-place.

Led · Series B · Nov 2020

Nurami Medical, founded in 2014 and based in Haifa, Israel, develops implants and sealants built on electrospun fibers and advanced materials to improve outcomes in soft tissue surgeries. Its inaugural product, ArtiFascia®, a novel dura repair graft, has been launched in the US and is awaiting CE approval. The company leverages unique combinations of electrospun polymers and smart materials and is advancing a second product that is currently in pre-clinical trials. Nurami will use the EIC funding to accelerate development of that second product. Management includes co-CEOs Nora Nseir Manassa and Hannoch Marksheid and co-founder Dr. Amir Bahar, who serves as COO and Clinical Director. Nurami Medical develops synthetic, biodegradable nanofiber technologies to support post-surgical healing and soft-tissue regeneration, with a lead product called ArtiFascia, a patented synthetic dural graft. ArtiFascia is designed to boost dura regeneration and prevent cerebrospinal fluid leakage after cranial neurosurgery. The company is running a clinical trial testing ArtiFascia in 90 patients, 13 of whom have already been implanted. Nurami is also developing additional products targeting the broader soft-tissue healing and regeneration market, estimated at $20 billion. The company plans to use recent funding to complete the ongoing clinical trial and to pursue FDA and CE regulatory approvals. Nurami was established in 2014 and is led by co-CEOs Nora Nseir Manassa (Co-CEO and CTO) and Hannoch Marksheid; Dr. Amir Bahar and NGT3VC were founders, and Doron Birger is active chairman of the board.